You have free access to this content

Cancer

Cover image for Cancer

1 March 2007

Volume 109, Issue 5

Pages 813–1002

  1. Review Articles

    1. Top of page
    2. Review Articles
    3. Original Articles
    1. You have free access to this content
      Markers of angiogenesis and clinical features in patients with sarcoma (pages 813–819)

      Steven DuBois and George Demetri

      Article first published online: 30 JAN 2007 | DOI: 10.1002/cncr.22455

      A number of measurable markers related to tumor angiogenesis have been studied in patients with sarcoma. Many of these studies demonstrate an association between tumor angiogenesis and clinical features in patients with sarcoma, including tumor size, tumor stage, and prognosis.

    2. You have free access to this content
      Updated clinical practice guidelines for the prevention and treatment of mucositis (pages 820–831)

      Dorothy M. Keefe, Mark M. Schubert, Linda S. Elting, Stephen T. Sonis, Joel B. Epstein, Judith E. Raber-Durlacher, Cesar A. Migliorati, Deborah B. McGuire, Ronald D. Hutchins and Douglas E. Peterson

      Article first published online: 18 JAN 2007 | DOI: 10.1002/cncr.22484

      Guidelines for the management of mucositis have been updated to reflect interim publications and advances in research and treatment. Sustained efforts in interdisciplinary research, assessment, and education are needed.

  2. Original Articles

    1. Top of page
    2. Review Articles
    3. Original Articles
    1. Disease Site

      Breast Disease
      You have free access to this content
      Early discontinuation of tamoxifen : A Lesson for oncologists (pages 832–839)

      Thomas I. Barron, Róisín Connolly, Kathleen Bennett, John Feely and M. John Kennedy

      Article first published online: 22 JAN 2007 | DOI: 10.1002/cncr.22485

      Within 1 year of commencing treatment the cumulative tamoxifen nonpersistence rate was 22.1% and by the end of follow-up at 3.5 years it had increased to 35.2%. The study demonstrates that persistence with tamoxifen cannot be assumed and raises concerns about persistence with other oral hormonal therapies for breast cancer and oral antineoplastics in general.

    2. Gastrointestinal Tract
      You have free access to this content
      Glutathione S-transferase gene polymorphisms and risk and survival of pancreatic cancer (pages 840–848)

      Li Jiao, Melissa L. Bondy, Manal M. Hassan, David Z. Chang, James L. Abbruzzese, Douglas B. Evans, Michael H. Smolensky and Donghui Li

      Article first published online: 30 JAN 2007 | DOI: 10.1002/cncr.22468

      Results from the current study suggested that the glutathione S-transferase P1 *C variant allele (105valine [Val]-114Val) was associated with a possibly reduced risk of pancreatic cancer in individuals aged >62 years and with significantly better survival in patients who were treated with 5-fluorouracil.

    3. You have free access to this content
      Common polymorphisms in 5-lipoxygenase and 12-lipoxygenase genes and the risk of incident, sporadic colorectal adenoma (pages 849–857)

      Zhihong Gong, James R. Hebert, Roberd M. Bostick, Zonglin Deng, Thomas G. Hurley, Dan A. Dixon, Daniela Nitcheva and Dawen Xie

      Article first published online: 18 JAN 2007 | DOI: 10.1002/cncr.22469

      The arginine (Arg) 261 glutamine (Gln) polymorphism in the 12-lipoxygenase (12-LOX) gene was associated with a decreased risk for colorectal adenoma, with particularly reduced risk for patients with a Gln variant allele who regularly took nonsteroidal anti-inflammatory drugs (Pinteraction = .02). However, there were no associations between either of the 2 polymorphisms in the 5-LOX gene and colorectal adenoma.

    4. Genitourinary Disease
      You have free access to this content
      Locally advanced prostate cancer—biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy (pages 858–867)

      Nicholas Bruchovsky, Laurence Klotz, Juanita Crook and S. Larry Goldenberg

      Article first published online: 30 JAN 2007 | DOI: 10.1002/cncr.22464

      The authors report on their analysis of serum testosterone and prostate-specific antigen (PSA) measurements from a prospective Phase II study of intermittent androgen suppression for men in biochemical recurrence after they received irradiation for locally advanced prostate cancer. The findings highlight the significance of baseline and nadir levels of serum PSA in predicting the early onset of androgen independence.

    5. You have free access to this content
      Prognostic ability of simplified nuclear grading of renal cell carcinoma (pages 868–874)

      Nathalie Rioux-Leclercq, Pierre I. Karakiewicz, Quoc-Dien Trinh, Vincenzo Ficarra, Luca Cindolo, Alexandre de la Taille, Jacques Tostain, Richard Zigeuner, Arnaud Mejean and Jean-Jacques Patard

      Article first published online: 29 JAN 2007 | DOI: 10.1002/cncr.22463

      The Fuhrman grade, in all the tested coding schemes, achieved independent predictor status. When multivariable predictive accuracy was assessed, the 3 Fuhrman grading schemes were equivalent in their ability to improve renal cell carcinoma-specific survival predictive accuracy.

    6. You have free access to this content
      Features of the metabolic syndrome and prostate cancer in African-American men (pages 875–881)

      Jennifer L. Beebe-Dimmer, Rodney L. Dunn, Aruna V. Sarma, James E. Montie and Kathleen A. Cooney

      Article first published online: 30 JAN 2007 | DOI: 10.1002/cncr.22461

      The association between specific features of the metabolic syndrome and prostate cancer was explored in a case-control study of African-American men. Hypertension and waist circumference >102 cm were observed more commonly among men with prostate cancer compared with controls.

    7. Gynecologic Oncology
      You have free access to this content
      Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma : DNA aneuploidy identifies high-risk cases among the so-called ‘low-risk’ patients with well and moderately differentiated tumors (pages 882–890)

      Tommaso Susini, Gianni Amunni, Cecilia Molino, Carlo Carriero, Stefano Rapi, Francesco Branconi, Mauro Marchionni, Gianluigi Taddei and Gianfranco Scarselli

      Article first published online: 29 JAN 2007 | DOI: 10.1002/cncr.22465

      DNA ploidy was the strongest independent prognosticator in a large series of endometrial cancers. Patients with advanced disease and DNA diploid tumor did significantly better than patients with FIGO stage I disease and DNA aneuploid tumor.

    8. Head and Neck Disease
      You have free access to this content
      Effects of α-tocopherol and β-carotene supplementation on upper aerodigestive tract cancers in a large, randomized controlled trial (pages 891–898)

      Margaret E. Wright, Jarmo Virtamo, Anne M. Hartman, Pirjo Pietinen, Brenda K. Edwards, Philip R. Taylor, Jussi K. Huttunen and Demetrius Albanes

      Article first published online: 30 JAN 2007 | DOI: 10.1002/cncr.22482

      In a randomized trial conducted in 29,000 Finnish male smokers, supplementation with vitamin E and/or β-carotene did not reduce the overall incidence of or mortality from site-specific upper aerodigestive tract cancers. However, β-carotene supplementation may impact the incidence of some subtypes of laryngeal tumors.

    9. Hematologic Malignancies
      You have free access to this content
      Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia (pages 899–906)

      Yasuhiro Oki, Hagop M. Kantarjian, Vazganush Gharibyan, Dan Jones, Susan O'Brien, Srdan Verstovsek, Jorge Cortes, Gail M. Morris, Guillermo Garcia-Manero and Jean-Pierre J. Issa

      Article first published online: 18 JAN 2007 | DOI: 10.1002/cncr.22470

      Resistance to imatinib is a frequent clinical problem in advanced phase chronic myelogenous leukemia (CML). The present study shows that a combination of low-dose decitabine, a DNA methyltransferase inhibitor, with imatinib is well tolerated and active in advanced phase CML without BCR-ABL kinase mutations.

    10. You have free access to this content
      Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib (pages 907–914)

      Florian Heidel, Jorge Cortes, Frank G. Rücker, Walter Aulitzky, Laurie Letvak, Thomas Kindler, Christoph Huber, Hartmut Döhner, Hagop Kantarjian and Thomas Fischer

      Article first published online: 6 FEB 2007 | DOI: 10.1002/cncr.22471

      The combination therapy of low-dose Ara-C and imatinib was applicable in an ambulatory setting with a median survival of 138 days, an early mortality rate of only 18.9%, and a low toxicity rate, with 2 patients showing hematologic improvement and 1 each with a partial response or complete response. Low-dose Ara-C/imatinib does not appear to be inferior in older acute myeloid leukemia patients in comparison with historic controls receiving myelosuppressive therapy.

    11. Hepatobiliary Tract
      You have free access to this content
      Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules (pages 915–923)

      Young Nyun Park, Masamichi Kojiro, Luca Di Tommaso, Amar P. Dhillon, Fukuo Kondo, Masayuki Nakano, Michiie Sakamoto, Neil D. Theise and Massimo Roncalli

      Article first published online: 5 FEB 2007 | DOI: 10.1002/cncr.22460

      Stromal invasion is 1 of the main features used to distinguish high-grade dysplastic nodules (DNs) from well-differentiated hepatocellular carcinomas (HCCs). In this study, the authors evaluated whether ductular reaction (DR) takes place around noninvasive hepatocellular nodules but not within the stroma contiguous to invasive HCC. DR characteristically was absent at the stromal invasive, leading edge of tumor cells in both minimally invasive HCCs and overtly invasive HCCs. The results indicated that DR/cytokeratin 7 immunostaining may help to identify small foci of invasion and to distinguish noninvasive, high-grade DNs from both minimally and overtly invasive HCCs.

    12. Lung Disease
      You have free access to this content
      A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer (pages 924–932)

      Leena Gandhi, Matthew W. Harding, Marcus Neubauer, Corey J. Langer, Melvin Moore, Helen J. Ross, Bruce E. Johnson and Thomas J. Lynch

      Article first published online: 6 FEB 2007 | DOI: 10.1002/cncr.22492

      A Phase II trial of the multidrug resistance inhibitor VX-710 in combination with doxorubicin and vincristine was conducted in patients with recurrent small cell lung cancer. There were a few durable responses, but hematologic toxicity was severe, and overall response criteria were not met to continue the study beyond Stage 1.

    13. You have free access to this content
      Novel marker D2-40, combined with calretinin, CEA, and TTF-1 : An optimal set of immunodiagnostic markers for pleural mesothelioma (pages 933–938)

      Takeshi Mimura, Akihiko Ito, Toshiko Sakuma, Chiho Ohbayashi, Masahiro Yoshimura, Noriaki Tsubota, Yutaka Okita and Morihito Okada

      Article first published online: 5 FEB 2007 | DOI: 10.1002/cncr.22477

      Large surgical specimens from 66 cases with pleural mesothelioma and 66 with lung adenocarcinoma were reevaluated. A 4-antibody immunohistochemical panel consisting of the novel mesothelial marker D2-40 as well as calretinin, CEA, and TTF-1 allowed the discrimination of epithelioid mesothelioma from lung adenocarcinoma with high sensitivity and specificity, leading to appropriate therapeutic strategy.

    14. You have free access to this content
      Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy (pages 939–948)

      Katsuyuki Hotta, Yoshiro Fujiwara, Keitaro Matsuo, Takeshi Suzuki, Katsuyuki Kiura, Masahiro Tabata, Nagio Takigawa, Hiroshi Ueoka and Mitsune Tanimoto

      Article first published online: 6 FEB 2007 | DOI: 10.1002/cncr.22478

      Few studies have assessed formally whether treatment outcomes have improved substantially over the years among patients with nonsmall cell lung cancer (NSCLC). In this study, by analyzing 121 Phase III trials of systemic chemotherapy for advanced NSCLC, a slow but steady improvement in patient outcome of 3.609 days per year was observed.

    15. Neuro-Oncology
      You have free access to this content
      Geminin: A good prognostic factor in high-grade astrocytic brain tumors (pages 949–956)

      Prabin Shrestha, Taiichi Saito, Seiji Hama, Muhamad T. Arifin, Yoshinori Kajiwara, Fumiyuki Yamasaki, Toshikazu Hidaka, Kazuhiko Sugiyama and Kaoru Kurisu

      Article first published online: 29 JAN 2007 | DOI: 10.1002/cncr.22474

      The findings from this study indicated that geminin is expressed highly in high-grade astrocytomas compared with low-grade astrocytomas and, thus, is a good prognostic factor for patients with these tumors. However, the higher expression of geminin in patients with high-grade astrocytomas indicated a more favorable outcome and longer survival in patients who received radiotherapy after surgery as a standard treatment protocol.

    16. Sarcoma
      You have free access to this content
      Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines (pages 957–965)

      Edith J. Mensah-Osman, Dafydd G. Thomas, Michelle M. Tabb, Jose M. Larios, Dennis P. Hughes, Thomas J. Giordano, Michelle L. Lizyness, James M. Rae, Bruce Blumberg, Paul F. Hollenberg and Laurence H. Baker

      Article first published online: 5 FEB 2007 | DOI: 10.1002/cncr.22479

      Approximately 30% to 40% of all patients with osteosarcomas ultimately experience recurrence. The study investigated the hypothesis that the resistance of osteosarcoma to chemotherapy may be related to the expression of a pregnane xenobiotic receptor (PXR) variant protein and its role as the major inducer of P450 3A4 in these tumors.

      Corrected by:

      Erratum: Erratum

      Vol. 119, Issue 5, 1115, Article first published online: 12 OCT 2012

    17. Discipline

      Epidemiology
      You have free access to this content
      Recurrences and second primary breast cancers in older women with initial early-stage disease (pages 966–974)

      Ann M. Geiger, Soe Soe Thwin, Timothy L. Lash, Diana S. M. Buist, Marianne N. Prout, Feifei Wei, Terry S. Field, Marianne Ulcickas Yood, Floyd J. Frost, Shelley M. Enger and Rebecca A. Silliman

      Article first published online: 22 JAN 2007 | DOI: 10.1002/cncr.22472

      Compared with younger women, older women are less likely to receive common breast cancer therapies. The current results indicated that radiation therapy after breast-conserving surgery and 5 years of tamoxifen use prevented recurrences and second primary breast cancers in older women, regardless of age or comorbidity burden.

    18. Medical Oncology
      You have free access to this content
      The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist (pages 975–982)

      Ruili Luo, Sharon H. Giordano, Dong D. Zhang, Jean Freeman and James S. Goodwin

      Article first published online: 30 JAN 2007 | DOI: 10.1002/cncr.22462

      Surgeons account for approximately 20% of the variation in patients seeing a medical oncologist. Interventions at the level of the surgeon may be appropriate to improve the care of patients with colon cancer.

    19. Disease Site

      Pediatric Oncology
      You have free access to this content
      Maternal and perinatal characteristics in relation to neuroblastoma (pages 983–992)

      Eric J. Chow, Debra L. Friedman and Beth A. Mueller

      Article first published online: 6 FEB 2007 | DOI: 10.1002/cncr.22486

      The authors conducted a population-based case-control study examining maternal, birth, and infant characteristics in relation to neuroblastoma. A significant association was observed with major congenital abnormalities, but not with most other characteristics.

    20. Discipline

      Translational Research
      You have free access to this content
      Single-injection ornithine decarboxylase-directed antisense therapy using atelocollagen to suppress human cancer growth (pages 993–1002)

      Kunihiko Nakazawa, Takahiro Nemoto, Tomoko Hata, Yousuke Seyama, Shunji Nagahara, Akihiko Sano, Hiroshi Itoh, Yutaka Nagai and Shunichiro Kubota

      Article first published online: 22 FEB 2007 | DOI: 10.1002/cncr.22483

      In vitro, ornithine decarboxylase antisense oligonucleotides in the atelocollagen remarkably suppressed MKN45, COLO201, and RD cell growth. A single administration of antisense oligonucleotides in the atelocollagen via 3 routes remarkably suppressed the growth of MKN45, COLO201, and RD tumor transplanted in nude mice.

SEARCH

SEARCH BY CITATION